My name is Inna Gertsenshteyn (EE-nah  GURTZ-en-shtine). I am a postdoctoral fellow at the Gordon Center for Medical Imaging at Massachusetts General Hospital and Harvard Medical School.

I received my Ph.D. in Medical Physics from the University of Chicago in 2022. My research focused on multi-modal imaging of tumor hypoxia to improve radiation therapy with Drs. Howard Halpern and Chin-Tu Chen.

I received my B.A. in Physics from Boston University in 2015.

Before starting graduate school in 2017, I worked as an Image Analyst at Invicro, a global research partner to pharmaceutical, biotech, and contract research organizations, aiming to enhance drug discovery and development. In early 2022 I did a co-op at Biogen in Late Discovery Imaging to gain industry experience.

My general research interests are in anything to do with multimodal imaging and image analysis. Outside of academia, I enjoy hosting house concerts, coffee dates with friends, going on walks, watching films, and reading. 

March 29th, 2023: Poster presentation at the Scientific Advisory Committee Virtual Meeting: "Nanoparticle Brachytherapy with Peritumoral [177Lu]Lu-Ferumoxytol Inhibits Glioma Xenograft Growth."

March 2023: Appointed as 2023-2025 intern for the Center for Molecular Imaging Innovation and Translation Board of Directors at SNMMI.

September 1st, 2022: Moved back to Boston for my postdoctoral fellowship at the Gordon Center for Medical Imaging.

July 18th, 2022: Ph.D. thesis defense scheduled to present my work on “Multi-Modal Imaging of Tumor Hypoxia to Improve Radiation Therapy”.

June 2022: Finished co-op at Biogen in Late Discovery Imaging, and back at the University of Chicago for my last quarter as  a PhD candidate.

March 10th, 2022: Invited talk at O2M Technologies. More info/registration link here.

January 2022: Starting a co-op at Biogen, while still on track to defend my PhD in the summer of 2022.

December 2nd, 2021: Oral presentation at the Radiological Society of North America Annual Meeting on "Validation of multimodal hypoxia imaging using pO2 EPR, FMISO PET, and DCE MRI with H&E, CD31, and HIF1 α staining on SCC7 squamous cell carcinomas." 

July 29th, 2021: Oral presentation at the International Society on Oxygen Transport to Tissue on "Validation and correction of [18]F-Misonidazole PET with pO2 EPR and
DCE-MRI."

June 12th, 2021: Selected as the 1st place CMIIT Young Investigator Award recipient at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting, for abstract titled “Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth.”

April 2021: Recipient of an NIH F31 Ruth L. Kirchstein National Research Service Award for my dissertation project: "Correcting [18]F-Misonidazole PET with MRI and EPR to improve hypoxia-guided radiation therapy."